- |||||||||| Darzalex IV (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma () - Nov 24, 2021 - Abstract #ASH2021ASH_6382;
P2
Recently, the GRIFFIN study evaluated the addition of the CD38 antibody, daratumumab to lenalidomide, bortezomib, and dexamethasone in transplant-eligible NDMM and demonstrated improved efficacy with an acceptable safety profile...CR (CR+sCR) rate after 4 cycles of Isa-KRd will be reported with 90% confidence interval. Support: Amgen and Sanofi
- |||||||||| Darzalex IV (daratumumab) / J&J, Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) () - Nov 24, 2021 - Abstract #ASH2021ASH_6315;
P1/2
Standard treatments for RRMM include daratumumab + pomalidomide + dexamethasone (DPd)andpomalidomide + bortezomib + low-dose dexamethasone (PVd)...Pts are enrolled into 3 treatment arms (non-randomized allocation; Figure): arm A, ide-cel + iberdomide (± dexamethasone), in cohorts 1 and 2 (per pt population), as maintenance therapy (subcohort a), or as both concurrent and maintenance therapy (subcohorts b and c; schedules differ); arm B, ide-cel + BMS-986405 as concurrent therapy; arm C, ide-cel + DPdor PVd as maintenance therapy...Lymphodepletion with fludarabine (30 mg/m 2 /day) and cyclosphosphamide (300 mg/m 2 /day) occurs for 3 consecutive days followed by 2 rest days before ide-cel infusion...Recruitment began in June 2021 and is ongoing in the United States and Spain. Study support bluebird bio and Celgene, a Bristol-Myers Squibb Company
- |||||||||| Adcetris (brentuximab vedotin) / Seagen, Takeda
New Onset Persistent Hyperglycemia with Initiation of Brentuximab Treatment () - Nov 24, 2021 - Abstract #ASH2021ASH_6260;
However, her last dose of dexamethasone was given more than ten days prior to her most recent FSBG reading of 220 mg/dL, so steroid-induced diabetes was deemed less likely...For many years, the standard of Hodgkin Lymphoma treatment consisted of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD)...Regardless of the mechanism of action, the above case report demonstrates a need to monitor blood glucose levels carefully during the initiation of BV therapy, especially in those individuals who have risk factors such as obesity or pre-diabetes mellitus. Future studies may further address the mechanism of hyperglycemia from BV and if the resultant diabetes is reversible.
- |||||||||| Campath (alemtuzumab) / Sanofi, Jakafi oral (ruxolitinib) / Novartis, Incyte, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
First Reported Case Series of Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD) () - Nov 24, 2021 - Abstract #ASH2021ASH_6247;
The patient underwent a conditioning regimen with melphalan 140 mg/m2, fludarabine 30 mg/m2 X5, and alemtuzumab for 5 days...Patient received steroids, extracorporeal photopheresis (ECP), and cellcept, and the GVHD resolved...The cGVHD persisted despite ibrutinib, ECP, tacrolimus, and sirolimus...The conditioning regimen was busulfan 2 mg/kg, fludarabine 30 mg/m2, cyclophosphamide 50 mg/kg, and thymoglobulin 2 mg/kg with tacrolimus as GVHD prophylaxis...Patient was placed on Fluticasone, Azithromycin, and Montelukast (FAM)...These findings may open the door for further concomitant use, especially if ruxolitinib is approved by the FDA for cGVHD. We propose further investigation into dual therapy of these drugs in cGVHD either compared to steroids or as a second line option.
- |||||||||| Darzalex IV (daratumumab) / J&J, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma: Old PLUS New Drugs in NOVEL Agents' Era () - Nov 24, 2021 - Abstract #ASH2021ASH_6168;
Median time to response was 1.3 months (r.1-3), median OS from diagnosis was 67.3 months (r.6-151), median OS from start of Bendamustine was 9.6 months (r.2-36). The triplet Bendamustine-Bortezomib-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT, also after failure of novel agents.
- |||||||||| dexamethasone / Generic mfg.
Journal: Osteoprotective Effect of Enamel Matrix Derivatives on the Regeneration of Mandibular Defects in Experimentally Glucocorticoid-Induced Osteoporosis. (Pubmed Central) - Nov 24, 2021
Three groups were subjected to induction of osteoporosis by subcutaneous injection of 0.1 mg/kg/day dexamethasone for 60 days...The percentage area of newly formed collagen fibers was significantly higher in group IV at 2nd week (13.96 ± 0.020%) and 4th week (16.95 ± 0.024%) than in group II (8.75 ± 0.015% and 10.29 ± 0.015%, respectively) and group III (12.93 ± 0.015% and 14.61 ± 0.021%, respectively), but was lower than that in group I (15.75 ± 0.015% and 17.49 ± 0.015%, respectively). The local application of emdogain combined with systemically injected calcitonin improves bone healing in surgically induced bone defects in osteoporotic rats.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: The Effect of Curcuma longa on Inflammatory Mediators and Immunological, Oxidant, and Antioxidant Biomarkers in Asthmatic Rats. (Pubmed Central) - Nov 24, 2021
In groups treated with dexamethasone and two higher concentrations of C. longa, neutrophil and eosinophil counts as well as TP, IL-4, and MDA levels were significantly decreased but IFN-γ, IFN-γ/IL-4 ratio, and antioxidants were increased (except IFN-γ/IL-4 ratio), compared to asthma group (p < 0.05 to p < 0.001). Compared to dexamethasone, C. longa exerted more pronounced effects on lung inflammation, oxidative stress, and immune system in asthmatic rats.
- |||||||||| methylprednisolone oral / Generic mfg., dexamethasone injection / Generic mfg.
Enrollment open: Steroid Administration for Articular Fractures of the Elbow (SAFE Trial) (clinicaltrials.gov) - Nov 24, 2021
P4, N=144, Recruiting,
Compared to dexamethasone, C. longa exerted more pronounced effects on lung inflammation, oxidative stress, and immune system in asthmatic rats. Not yet recruiting --> Recruiting
- |||||||||| Darzalex IV (daratumumab) / J&J
Clinical, Journal: Immunomodulation in pomalidomide, dexamethasone, and daratumumab -treated relapsed/refractory multiple myeloma patients. (Pubmed Central) - Nov 24, 2021
P2
Further, DARA antimyeloma activity and elimination of CD38+ T cells (regulatory/activated) provides a rationale for therapeutic combination with direct tumoricidal activity and immunomodulation of POM-directed T cell enhancements. These data highlight enhancements in immune subpopulations for the combination of DARA with POM and potentially with next generation cereblon-targeting agents.
- |||||||||| dexamethasone / Generic mfg.
Clinical, Journal: A rare case of ectopic ACTH syndrome with rhabdomyolysis. (Pubmed Central) - Nov 24, 2021
RM is a rare complication of EAS with insidious onset and atypical clinical manifestations. Serum potassium levels should be vigilantly monitored to avoid RM in EAS.
- |||||||||| dexamethasone / Generic mfg.
Journal: A complete heart regeneration model with inflammation as a key component. (Pubmed Central) - Nov 24, 2021
Dexamethasone (Dex) was used to inhibit inflammation and its effects on heart regeneration were evaluated...These demonstrated that cardiomyocytes death and heart regeneration occurred in this model and inflammation might play a crucial role in it. Modulating inflammation may provide a promising therapeutic strategy to support heart regeneration.
- |||||||||| dexamethasone injection / Generic mfg.
Clinical, P2 data, Journal: A Randomized, Multicenter, Open-Label, Blinded End Point, Phase 2, Feasibility, Efficacy, and Safety Trial of Preoperative Microvascular Protection in Patients Undergoing Major Abdominal Surgery. (Pubmed Central) - Nov 24, 2021
Intravenous dexamethasone and albumin administration was feasible but did not reduce syndecan-1 on POD 1 in patients undergoing abdominal surgery. Given the clinically important CIs observed between the groups for heparan sulfate, CRP, and postoperative complications, a larger trial assessing the associations between dexamethasone and albumin administration and these outcomes is warranted.
- |||||||||| aspirin / Generic mfg.
Enrollment open: PASTA: High Dose Steroids in Children With Stroke (clinicaltrials.gov) - Nov 24, 2021
P3, N=70, Recruiting,
TAM depletion was more effective than PMN- or M-MDSCs depletion at boosting the anti-tumor response of T cell engaging BsAb. Not yet recruiting --> Recruiting
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Long-term in-vitro glucocorticoid treatment induces glucocorticoid resistance in canine mast cell tumors. (Pubmed Central) - Nov 24, 2021
The objective of this study was to establish glucocorticoid-resistant canine MCT cell lines derived from glucocorticoid-sensitive cell lines after prolonged treatment with dexamethasone (Dex)...These cell lines suggest that multiple mechanisms contribute to glucocorticoid resistance in canine MCT cells. The mechanisms of glucocorticoid resistance after long-term treatment can be further investigated using these cell lines and a novel therapeutic strategy for glucocorticoid-resistant canine MCT cells can be developed.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Clinical, Journal: Case Report: Post-Chikungunya-Associated Myeloneuropathy. (Pubmed Central) - Nov 24, 2021
At 20-week follow-up, the patient had improvement in upper limb weakness, but paraparesis persisted. The case highlights the presence of unusual MRI findings and also the importance of early recognition of after infective neurological complications, and prompt treatment with immunomodulation may be beneficial.
- |||||||||| dexamethasone / Generic mfg.
Review, Journal: Occurrence, Fate, Effects, and Risks of Dexamethasone: Ecological Implications Post-COVID-19. (Pubmed Central) - Nov 24, 2021
To improve DEXA management, toxicological outcomes of DEXA and formed TPs should entail long-term studies from whole organisms to molecular effects in actual environmental matrices and at realistic exposure concentrations. This can aid in striking a fine balance of saving human lives and protecting ecological integrity.
- |||||||||| Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: ClaSPd: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (clinicaltrials.gov) - Nov 23, 2021
P2, N=26, Recruiting,
Taken together, our study demonstrates that the combination of HC + EB-1 is an efficacious countermeasure to HN2. Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Nov 2024 | Initiation date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jun 2023 --> Nov 2023
- |||||||||| Neofordex (dexamethasone acetate high-dose) / CTRS Laboratories
Trial completion date, Trial initiation date, Trial primary completion date: IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) - Nov 22, 2021
P3, N=272, Not yet recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Nov 2024 | Initiation date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jun 2023 --> Nov 2023 Trial completion date: Apr 2025 --> Jul 2026 | Initiation date: Oct 2021 --> Jan 2022 | Trial primary completion date: Oct 2024 --> Jan 2025
- |||||||||| methylprednisolone acetate / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Trial completion date, Trial primary completion date: Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone (clinicaltrials.gov) - Nov 22, 2021
P4, N=1000, Suspended,
Trial completion date: Apr 2025 --> Jul 2026 | Initiation date: Oct 2021 --> Jan 2022 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial completion date: Aug 2021 --> Mar 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Trial completion date, Trial primary completion date: High Dose Carfilzomib for Newly Diagnosed Myeloma (clinicaltrials.gov) - Nov 22, 2021
P1/2, N=37, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- |||||||||| dexamethasone / Generic mfg.
Review, Journal: Non-coding RNA basis of muscle atrophy. (Pubmed Central) - Nov 22, 2021
Muscle atrophy is a common complication of many chronic diseases including heart failure, cancer cachexia, aging, etc. Unhealthy habits and usage of hormones such as dexamethasone can also lead to muscle atrophy...This review mainly discusses the regulation of ncRNAs in muscle atrophy induced by various factors such as heart failure, cancer cachexia, aging, chronic obstructive pulmonary disease (COPD), peripheral nerve injury (PNI), chronic kidney disease (CKD), unhealthy habits, and usage of hormones; highlights the findings of ncRNAs as common regulators in multiple types of muscle atrophy; and summarizes current therapies and underlying mechanisms for muscle atrophy. This review will deepen the understanding of skeletal muscle biology and provide new strategies and insights into gene therapy for muscle atrophy.
|
